The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Sourcing

research use only

Material not approved for human use, sold for laboratory research.

56 topics 18 solved Group: Sourcing

Related in this group: certificate of analysis · batch & lot numbers · Janoshik Analytical · Medutest · PeptideMeter · VendorInvestigate · third-party testing · blind sampling · documentation quality · underdosing · mislabelling · customs

56 topics · page 2 of 2

TopicParticipantsRepliesViewsActivity
Payment mechanics and the recovery options that do not exist
Payment mechanics and the recovery options that do not exist Writing it up because I had to work it out twice and would rather nobody else did. I would like to talk about documentation quality as a signal,…
INDDNMFI+80 89 24k 9mo
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Session topic: SELECT ( N Engl J Med , 2023). Please read…
DBETRT 2 309 9mo
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…
MKJSMSRFF+81 87 35k 10mo
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
NEHFDBBKLG+62 66 26k 10mo
Payment method and the leverage it gives you, ranked
Posting this under the heading it deserves: Payment method and the leverage it gives you, ranked Everything below is what sits behind that. Structured report rather than an opinion, following the format the…
GITKPNHAPK+71 76 56k 10mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
DHKAV 2 5k 11mo
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
CHDVRARZMD+76 82 52k 11mo
Coming back to: When "no data" is the complete and final answer
When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
LVAVHAPNV+77 82 12k 11mo
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
FNSRMFSTRH+107 119 11k 12mo
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
BNGVIAJVGE+104 114 10k 12mo
Payment mechanics and the recovery options that do not exist — what changed since
On the subject in the title: Payment mechanics and the recovery options that do not exist — what changed since Working notes rather than a conclusion. A logistics question, since the answers here are usually…
YRVBENBDCP+14 18 17k 13mo
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…
NSJRIBTYCC+28 32 640 13mo
Second pass at: How to research a compound with no human data without deceiving yourself
Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…
SVKBISCGP+64 71 2.5k 13mo
Second pass at: A payment that went through twice: how it was resolved
On the subject in the title: Second pass at: A payment that went through twice: how it was resolved Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
AKCDVB 2 1.1k 14mo
Research-use-only labelling: what it means and what it does not — the long version
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. I would like to talk about…
GLSHKKK+150 158 55k 14mo
When "no data" is the complete and final answer
Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…
NPNTPOSPNS+154 165 6.3k 15mo
What to keep a record of at the point of payment
What to keep a record of at the point of payment — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following the format the…
HFBRAN 2 1.8k 16mo
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…
TWONMSRFF+109 125 2k 16mo
How compounding permissions changed when supply normalised
Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…
GCCCCCMEMP+30 34 51k 16mo
Pharmaceutical compounding rules, summarised from primary sources
Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
BJMBEDRIIL+135 163 46k 17mo
Follow-up: Why this community will not facilitate a group purchase
Why this community will not facilitate a group purchase I have a specific reason for asking rather than idle curiosity, and the context is below. A logistics question, since the answers here are usually…
WNMGVS 2 19k 18mo
About the Payments category
Payment mechanics, chargeback reality, and the recurring risks. No payment facilitation of any kind here. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
KHSSHKM 4 3.5k 20mo
Coming back to: Research-use-only labelling: what it means and what it does not
Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
RDCCAAPSDO+45 50 39k 20mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile
Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with…
NATKBANDB+119 141 22k 20mo
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…
APAWCEBWGR+7 11 5.5k 20mo
Naming conventions for research peptides and the confusion they cause — one year on
Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in…
CPLCVSMSCV+1 5 181 2y